Treatment library
Loading treatment roster
Preparing current medications, procedures, devices, and historical context.
Treatment library
Preparing current medications, procedures, devices, and historical context.
An older short-term sympathomimetic obesity medication that remains available but sits well outside the current branded-incretin spotlight.
FDA-approved for short-term obesity treatment.
Sympathomimetic appetite suppression
Coverage is inconsistent, but cash-pay cost is often lower than branded obesity drugs.
Sympathomimetic appetite suppression
An older short-term sympathomimetic obesity medication that remains available but sits well outside the current branded-incretin spotlight.
medication
current
1960
generic benzphetamine
benzphetamine
Multiple generic manufacturers
Yes.
benzphetamine
Generally lower-cost generic-style therapy compared with branded obesity medications.
Coverage is inconsistent, but cash-pay cost is often lower than branded obesity drugs.
Mostly relevant as part of the older stimulant pharmacotherapy set.
Benzphetamine matters mainly for completeness because it is still part of the older U.S. obesity-medication toolkit.
Cardiovascular, insomnia, and misuse concerns limit enthusiasm in modern practice.
insomnia, dry mouth, palpitations, restlessness, elevated blood pressure
Sympathomimetic appetite suppression
Oral tablet used short term as part of a calorie-restricted regimen.
Oral tablet.
These are the official or reference sources used to anchor this treatment profile.
Treatment availability, dosing, cash pricing, and insurance coverage change often. Verify current details with your clinician, pharmacist, surgeon, device program, and insurer before starting, switching, or paying for treatment.